

Board Seal

RECEIVED
SEP 11 2003
MISSOURI BOARD
OF PHARMACY

3

)

1

3

1

2

1

1

1

Respondent acknowledges that it understands the various rights and privileges afforded it by law, including the right to appear and be represented by counsel; the right to have a copy of the Complaint served upon it by the Missouri Board of Pharmacy prior to the entering of its order; the right to have all charges against it proven upon the record by competent and substantial evidence; the right to cross-examine any witness appearing

at the hearing against it; the right to present evidence on Respondent's own behalf at the hearing; the right to a decision upon the record by the Board concerning the charges pending against it; and the right to a ruling on questions of law by the Board. Being aware of these rights provided it by operation of law, Respondent knowingly and voluntarily waives each and every one of these rights and freely enters into this Joint Motion for Consent Order, Joint Stipulation of Facts, Waiver of Hearing Before the Missouri Board of Pharmacy and Joint Stipulation and Disciplinary Order with Joint Stipulated Findings of Fact and Conclusions of Law ("Joint Stipulation and Disciplinary Order") and agrees to abide by the terms of this document, as they pertain to it.

Based upon the foregoing, the parties jointly stipulate to the following and request that the Missouri Board of Pharmacy adopt as its own the Joint Stipulated Findings of Fact and the Joint Stipulated Conclusions of Law as to the Board's Findings of Fact and Conclusions of Law.

JOINT STIPULATION OF FACTS AND CONCLUSIONS OF LAW

1. The Missouri Board of Pharmacy ("the Board"), is an agency of the State of Missouri created and established by § 338.110, RSMo, for the purpose of administering and enforcing the provisions of Chapter 338, RSMo.

2. Respondent, Med-E-Quip, is licensed by the Missouri Board of Pharmacy as a drug distributor, as defined in § 338.330 RSMo. Respondent's license, numbered DD2003026499, is current and active as of the date of this Joint Stipulation and Disciplinary Order.

3. Robert A. Caples is the President and Manager-In-Charge of Med-E-Quip.

4. Med-E-Quip's permit was current and active at all times relevant herein.

5. Respondent Med-E-Quip has represented that it is involved in the purchase and sale of new and used infusion pumps and the resale of pre-packaged IV administration infusion pump sets. Respondent Med-E-Quip has further represented that it is not currently involved in the purchase, sale, or storage of prescription medications or IV fluids for human use.

6. On or about April 14, 2008, Respondent entered into a *Settlement Agreement Between State Board of Pharmacy and Med-E-Quip Locators, Inc.* ("Settlement Agreement") whereby Med-E-Quip's permit was placed on probation for a period of three (3) years expiring on or about April 28, 2011. A true and correct copy of the *Settlement Agreement* is attached hereto as Exhibit A and incorporated herein by reference.

7. The three (3) years probation was imposed, in part, due to Respondent's failure to timely notify the Board of a change in the manger-in-charge at Med-E-Quip.

8. Under the Settlement Agreement executed by Respondent on April 14, 2008, the terms of Respondent's three (3) year probation include the following provisions:

* * *

3. Licensee shall comply with all provisions of Chapter 338, Chapter 195, RSMo, and all applicable federal and state drug laws, rules and regulations and with all federal and state criminal laws . .

* * *

7. Licensee's failure to comply with any condition of discipline set forth herein constitutes a violation of this disciplinary Order.

9. On April 22, 2008, Respondent executed a Drug Distributor Location

Change Application which requested the Board's approval for a change in location of its facilities. The Drug Distributor Location Change Application was received by the Board on April 25, 2008.

10. 20 CSR 2220-5.020(6) provides that any new location be approved by Board inspectors if a drug distributor intends to change the location of its currently licensed facility.

11. The Board received a Drug Distributor Location Change Application from Med-E-Quip on or about April 25, 2008 showing the effective date of change to be April 1, 2008.

12. On or about May 22, 2008, Tom Glenski and Steve Smith, Inspectors for the Board, conducted a change of location inspection at Med-E-Quip's new location at 2505 Metro Blvd., Suite M, Maryland Heights, Missouri.

13. During this inspection, Inspectors Glenski and Smith discovered that Med-E-Quip began conducting business at the 2505 Metro Blvd., Suite M, Maryland Heights location some time during the third week of February, 2008.

14. On September 22, 2008, Med-E-Quip's Vice President, Mr. Pat Postal, admitted that Med-E-Quip started conducting business at its new location around the third week in February, 2008.

15. Med-E-Quip conducted business at its new location for approximately two (2) months prior to notifying the Board of its change of location.

16. Med-E-Quip did not notify the Board of its change in location prior to conducting business at the new location.

17. Med-E-Quip's failure to notify the Board of its change of location prior to

conducting business at the new location is in violation of 20 CSR 2220-5.020(6) which states in pertinent part:

(6) If an individual or business entity operating a drug distributor facility changes the location of the facility either within the existing facility (structure) or to a new facility (structure), the facility shall not open for business at the new location until the board, its duly authorized agent or the Food and Drug Administration has inspected the premises of the new location and approved it and the facility has been in compliance with all state and federal drug laws pertaining to drug distribution. Upon this approval and receipt of a change of location fee, the board shall issue a license authorizing operation of a facility at the new location and the license shall bear the same number as the previous license. However, the license remains valid if the facility address changes, but not the location, and an amended license will be issued without charge under these circumstances.

18. Med-E-Quip's failure to notify the Board of its change of location prior to conducting business at the new location violates the terms of the April 14, 2008 *Settlement Agreement* in that Med-E-Quip failed to comply with all applicable drug rules and regulations by failing to comply with 20 CSR 2220-5.020(6).

19. A review of Med-E-Quip's receipt records was conducted by Board Inspectors which revealed that Med-E-Quip purchased and received infusion pumps and IV tubing from several different suppliers who were not licensed distributors with the State of Missouri.

20. Med-E-Quip's receipt records indicated the following information about its infusion pumps and IV tubing business:

| Receive Date | Product | Supplier | PO Number |
|--------------|---------------|---|-----------|
| 02/21/2008 | CADD 6161 | Simple Solutions 100 Miller St Suite 1 Blacksburg, VA 24060 | 10272 |
| 01/10/2008 | Colleague 3CX | Tri-Med 453 Callen Avenue Morgantown, WV 26501 | 10212 |
| 08/12/2008 | Colleague 1, | Texus Medical | 10740 |

| | | | |
|---------------------------|--|--|--------|
| | Colleague 3 | 2001 Franklin Ave. Waco, TX 76701 | |
| 07/17/2008 | Abbott Encore | Universal Hospital Services 7700 France Ave South Suite 275 Edina, MN 55435 | 10714 |
| 04/22/2008 | Baxter 6300, Baxter 6201 | Quest Medical Supply 600 Sweetwater Club Circle Longwood, FL 32779 | 10502 |
| 03/31/2008 | CADD 6161 VIP | Novatek Medical Rental Group 1609 West Wernsing Ave. Effingham, IL 62401 | 10382 |
| 06/06/2007, 07/10/2008 | Braun Vista Basic | Northwest Florida Hematology & Oncology 11 West 23rd Street Suite C Panama City, FL 32405 | 9709 |
| 09/02/2008 | Baxter 6301, Baxter 6201 | Mike Mathis 615 Main Ave. North Magee, MS 39111 | 10774 |
| 08/26/2008 | Abbott Encore | Auction: EBAY Pine Run Community 777 Ferry Road Doylestown, PA 18901 | 10768 |
| 07/22/2008 | Baxter 6301, Baxter 6201 | Ideal Medical Equipment 121 Milledge Ave. Monroe, GA 30655 | 10544 |
| 08/29/2008 | CADD 6100 VIP | Inter Mountain Medical 779 South 200 East Suite A Salt Lake City, UT 84111 | 10792 |
| 05/21/2008 | Sigma 8000, Sigma 8000 Plus | Good-Bye Auction 2669 NE Twin Knolls Dr. #208 Bend, OR 97701 | 10527A |
| 03/17/2008 | Abbott Plum XL3, Abbott Plum XLD | Global Medical Brokers 5104 Criterion Way Dublin, OH 43016 | 10255 |
| 04/18/2008 | Sims Deltec AVI 200A | Freedom Medical, Inc. 219 Welsh Pool Rd Exton, PA 19341 | 10507 |
| 06/24/2008 | Baxter PCA II | Farwest Medical 2130 82nd Dr. NE Everett, WA 08205 | 10531 |
| 12/22/2006 | Horizon NXT | Firstenberg Machinery Company, Inc. 867 South 19th Street Richmond, CA 94894 | 8982 |
| 02/19/2008 | Alaris Signature 7230 | Equip Stat Medical Inc. 1461 Harbour Walk Road Tampa, FL 33609 | 10245 |
| 06/16/2008 | Horizon NXT | Drand Medical 7633 Northwest 3rd Oklahoma City, OH 73127 | 10539 |
| 06/09/2008 | Alaris Signature | Auction: Dotmed.com, Inc | 10536 |

| | | | |
|------------|--|---|--------|
| | 7230, Alaris Signature 7130 | 29 Broadway Suite 2500 New York, NY 10006 | |
| 05/20/2008 | Secure 3000ml dual chamber, 1500ml dual Chamber | Clinical Technology, Inc. One Corporate Center Broadview Heights, OH 44147 | 10456 |
| 04/18/2008 | CADD 6101 VIP, Baxter AS 50 | Auction: Centurion Service Group 1400 N 25th Ave. Melrose, IL 60160 | 10395 |
| 05/15/2008 | Baxter 6200 | Concord Parkway Animal Hospital 308 Concord Parkway North Concord, NC 28027 | 10355 |
| 07/08/2008 | Baxter I Pump | BMX Medical, Inc. 1301 Cambridge Street, Suite 111A Minneapolis, MN 55243 | 10596 |
| 07/17/2008 | Alaris Signature 7130E | Blue Lake Services 34201 Melinz Parkway, Unit B Eastlake, OH 44095 | 10719 |
| 07/17/2008 | Alaris Signature 7130E | Biomedix Medical 205 Maple Lane Toughkenamon, PA 19374 | 10584 |
| 02/20/2008 | Cadd 6101 | Ardus Medical, Inc. 11297 Grooms Road Cincinnati, OH 45242 | 10282 |
| 04/07/2008 | Alaris IVAC Medsystem 2863 | Auction: GSA Auction VAMC 1030 Jefferson Ave. Memphis, TN 38104 | 10389 |
| 01/30/2008 | Braun Vista Basic, Baxter 6200 | BPAI LLC 901 Curtain Ave. Baltimore, MD 21218 | 10241 |
| 12/13/2007 | Baxter AS 50 | GVS-NY 46 Central Ave. Farmingdale, NY 11735 | 10176 |
| 03/07/2008 | Braun Vista Basic, Sigma 6000+2.2 M | Arthur Sunkin, MD 3 Colonial Green Loudenville, NY 12211 | 10353 |
| 08/27/2008 | Baxter AS 50 | Anda Medical 21 Donnington Place Ottawa, Ontario K2H7K9 | 10780 |
| 07/25/2008 | IMED PC-2TX | Auction: EBAY Lee Temple 2886 Magnolia Blossom Lane Marianna, FL 32446 | 10553A |
| 07/08/2008 | Abbott Plum A+ | Auction: EBAY Matrix Medical 1936 Cedar Lake Parkway Minneapolis, MN 55416 | 10708 |
| 01/28/2008 | Baxter Colleague CX | Auction: EBAY Sheila Gibbs POB 3441 Edgewood, NM 87015 | 10204 |
| 01/08/2008 | Baxter 6201 | Auction: EBAY | 10157 |

| | | | |
|------------|----------------------------|--|--------------------------------|
| 09/10/2007 | Baxter 6201 | Auction: EBAY Tami & Joe Galipo 107 Scotsburg Drive Warner Robbins, GA 31088 | 9945 |
| 01/23/2008 | Colleague 1 | Auction: GSA VAMC Temple 819 Taylor Street Fort Worth, TX 76102 | 10238 |
| 06/12/2008 | Deltec Legacy | Medical Solutions, Inc. 8406 Magnolia Ste. A Santee, CA 92071 | 10571-B |
| 01/23/2008 | Clear link Solution set | Auction: GSA VAMC Temple 819 Taylor Street Fort Worth, TX 76102 | Provided free with PO 10238 |

21. None of the suppliers listed in the table set forth in paragraph 20 above are licensed or registered drug distributors in the State of Missouri.

22. Med-E-Quip's practice of purchasing infusion pumps and IV tubing from suppliers not licensed or registered by the Board is in violation of 20 CSR 2220-5.020(1) which states in pertinent part:

(1) . . . No wholesale drug distributor with physical facilities located in the state of Missouri shall knowingly purchase or receive legend drugs and/or drug related devices from a wholesale drug distributor or pharmacy not licensed or registered by the board . . .

23. Med-E-Quip's purchase and receipt of infusion pumps and IV tubing from suppliers not licensed or registered by the Board after April 14, 2008 is in violation of the terms of the April 14, 2008 *Settlement Agreement* in that Med-E-Quip failed to comply with all applicable drug rules and regulations by failing to comply with 20 CSR 2220-5.020(1).

24. With regard to purchase orders no. 10272, 10255, 10282, 10527, 10395, 10355, and 10353 set forth in paragraph 20 above, these orders were shipped directly to Med-E-Quip's new facility at 2505 Metro Blvd, Suite M, Maryland Heights, MO 63040 prior to the change of location inspection on May 22, 2008.

25. With regard to purchase orders no. 10272, 10740, 10714, 10502, 10382, 10774, 10768, 10544, 10792, 10507, 10531, 10539, 10536, 10456, 10527, 10255, 10282, 10596, 10719, 10708, 10571 and 10353 set forth in paragraph 20 above, these orders were shipped directly to Med-E-Quip's new facility at 2505 Metro Blvd, Suite M, Maryland Heights, MO 63040 prior to the Board's approval of a change of location on August 21, 2008.

26. All of the equipment described by the purchase orders listed in paragraph 20 above were transferred to Med-E-Quip's new facility at 2505 Metro Blvd., Suite M, Maryland Heights, MO 63040 prior to the Board's approval of that site on August 21, 2008.

27. During the inspection on May 22, 2008, it was discovered that Med-E-Quip's facilities lacked any equipment to monitor temperature or humidity.

28. Med-E-Quip's lack of equipment to monitor temperature and humidity within the facility was a violation of 20 CSR 2220-5.030(3)(B) which states:

(3) Minimum standards of practice for drug distributors shall include the following:

(B) The temperature of the facility where drugs are stored must be maintained thermostatically within temperature requirements as provided for by the manufacturer or the latest edition of the *United States Pharmacopeia* (USP). Appropriate manual, electromechanical, or electronic temperature and humidity recording equipment, devices, logs, or all of these, shall be utilized to document proper storage of prescription drugs.

29. Med-E-Quip has, since the time of its May 22, 2008 inspection, remedied its violation of 20 CSR 2220-5.030(3)(B) by installing appropriate temperature and humidity controls at its facility.

30. Med-E-Quip's initial failure to maintain equipment to monitor temperature and humidity within the facility violated the terms of the April 14, 2008 *Settlement Agreement* in that Med-E-Quip failed to comply with all applicable drug rules and regulations.

31. During the inspection on May 22, 2008, it was discovered that Med-E-Quip did not maintain an alarm system for the facility.

32. Med-E-Quip's failure to equip the facility with an alarm system was a violation of 20 CSR 2220-5.030(3)(C)(13) which states:

(3) Minimum standards of practice for drug distributors shall include the following:

(C) Appropriate housekeeping, sanitation, lighting, ventilation and humidity of all areas where drugs are stored must be maintained.

13. All facilities shall be equipped with an alarm system to detect entry after hours.

33. Med-E-Quip has, since the time of its May 22, 2008 inspection, remedied its violation of 20 CSR 2220-5.030(3)(C)(13) by installing an appropriate alarm system at its facility.

34. Med-E-Quip's initial failure to equip the facility with an alarm system violated the terms of the April 14, 2008 *Settlement Agreement* in that Med-E-Quip failed to comply with all applicable drug rules and regulations.

35. Due to multiple violations of applicable rules and regulations identified during the May 22, 2008 inspection, Med-E-Quip failed to pass an inspection of its facility for a change in location until August 21, 2008.

36. Med-E-Quip conducted business at its new location for approximately six

(6) months before its new site was approved by the Board inspectors for operation.

37. The Board is authorized to impose additional discipline pursuant to Section 338.055.3, RSMo, which states in pertinent part:

. . . The board may impose additional discipline on a licensee, registrant or permittee found to have violated any disciplinary terms previously imposed under this section or by agreement.

JOINT AGREED DISCIPLINARY ORDER

Based upon the foregoing, the parties mutually agree and stipulate that the following shall constitute the disciplinary order entered by the Board in this matter under the authority of §621.045.3, RSMo (2000). This disciplinary order will be effective immediately upon the issuance of the Consent Order of the Missouri Board of Pharmacy without further action by either party.

1. Respondent's license as a drug distributor shall be placed on PROBATION for a period of five (5) years. The period of probation shall constitute the disciplinary period. The terms of discipline shall be as follows:

A. Respondent shall pay all required fees for licensing to the Board and shall renew its license prior to October 31 for each licensing year.

B. Respondent shall comply with all provisions of Chapter 338, Chapter 195, and all applicable federal and state drug laws, rules and regulations and with all federal and state criminal laws. "State" here includes the State of Missouri and all other states and territories of the United States.

C. If, after disciplinary sanctions have been imposed, the Respondent fails to keep its drug distributor license current, the period of unlicensed status

shall not be deemed or taken as any part of the time of discipline so imposed.

D. Respondent shall report to the Board, on a preprinted form supplied by the Board office, once every six months (due by each January 1 and July 1), beginning with whichever date occurs first after this Order/Agreement becomes effective, stating truthfully whether or not it has complied with all terms and conditions of its disciplinary order.

E. Respondent shall select an independent consultant for the purpose of reviewing and insuring all compliance measures are carried out in accordance with all applicable laws and regulations. Respondent shall submit documentation and credentials of its chosen consultant to the Board office for approval prior to the beginning date of probation. Said consultant shall submit a written plan to the board office outlining what procedures or changes in operation will be implemented and on what time table is proposed for completion. The consultant shall then provide ongoing reports to the Board office attesting to the drug distributor's compliance or noting deficiencies for each visit made. The visits and initial report shall be provided within sixty (60) days of the beginning of probation. Visits to the drug distributor to assess compliance will be completed at a minimum of a 6 month cycle and reports to the Board office will be provided once every 6 months throughout the disciplinary period. The consultant shall be hired at Respondent's expense.

F. Respondent shall make a representative of the drug distributor available for personal interviews to be conducted by a member of the Board or the Board of Pharmacy staff. Said meetings will be at the Board's discretion and may

occur periodically during the disciplinary period. Respondent will be notified and given sufficient time to arrange these meetings.

G. Respondent's failure to comply with any condition of discipline set forth herein constitutes a violation of the disciplinary Joint Stipulation and Disciplinary Order.

H. The parties to this Joint Stipulation and Disciplinary Order understand that the Board of Pharmacy will maintain this Joint Stipulation and Disciplinary Order as an open record of the Board as provided in Chapters 324, 338 and 610, RSMo.

2. The parties agree that this Joint Stipulation and Disciplinary Order resolves all allegations contained in the complaint in this matter and none of those allegations will be the subject of any further litigation between the parties. The parties further agree that this Joint Stipulation and Disciplinary Order and any statements contained therein may not be used for or constitute an admission or finding for any purpose other than to settle the disputes between the parties. The parties further agree that this Joint Stipulation and Disciplinary Order and any statements contained therein shall not be construed as an admission of any guilt or liability, civil or criminal, by Respondent.

3. The Joint Stipulation and Disciplinary Order does not bind the Board or restrict the remedies available to it concerning any other violation of Chapter 338, RSMo, by Respondent not specifically mentioned in this document.

4. Upon the expiration of the disciplinary period, Respondent's drug distributor license shall be fully restored if all requirements of law have been satisfied;

provided, however, that in the event the Board determines that the Respondent has violated any term or condition of this Joint Stipulation and Disciplinary Order, the Board may, in its discretion, vacate this Joint Stipulation and Disciplinary Order and impose such further discipline as the Board shall deem appropriate.

5. No additional order shall be entered by this Board pursuant to the preceding paragraph of this Joint Stipulation and Disciplinary Order without notice and an opportunity for hearing before this Board as a contested case in accordance with the provisions of Chapter 536, RSMo. If any alleged violation of this Joint Stipulation and Disciplinary Order occurred during the disciplinary period, the parties agree that the Board may choose to conduct a hearing before it either during the disciplinary period or as soon thereafter as a hearing can be held to determine whether a violation occurred and, if so, may impose further disciplinary action. Respondent agrees and stipulates that the Board has continuing jurisdiction to hold a hearing to determine if a violation of this Joint Stipulation and Disciplinary Order has occurred.

6. If the Board determines that Respondent has violated a term or condition of this Joint Stipulation and Disciplinary Order, which violation would also be actionable in a proceeding before the Administrative Hearing Commission or the circuit court, the Board may elect to pursue any lawful remedies or procedures afforded it and is not bound by this Joint Stipulation and Disciplinary Order in its determination of appropriate legal actions concerning that violation.

7. Each party agrees to pay all its own fees and expenses incurred as a result of this case and litigation.

8. The terms of this Joint Stipulation and Disciplinary Order are contractual, legally enforceable, binding and not merely recitals. Except as otherwise contained herein, neither this Joint Stipulation and Disciplinary Order nor any of its provisions may be changed, waived, discharged, or terminated, except by an instrument in writing signed by the party against whom the enforcement of the change, waiver, discharge, or termination is sought.

9. Respondent, together with its successors heirs and assigns, and its attorneys, do hereby waive and release, acquit and forever discharge the Board, its respective members and any of its employees, agents, or attorneys, including any former board members, employees, agents, and attorneys, of, or from, any liability, claim, actions, causes of action, fees, costs and expenses, and compensation, including, but not limited to, any claims for attorney's fees and expenses, including any claims pursuant to Section 536.087, RSMo, or any claim arising under 42 U.S.C. Section 1983, which may be based upon, arise out of, or relate to any of the matters raised in this litigation, or from the negotiation or execution of this Joint Stipulation and Disciplinary Order. The parties acknowledge that this paragraph is severable from the remaining portions of this Joint Stipulation and Disciplinary Order in that it survives in perpetuity even in the event that any court of law deems this Joint Stipulation and Disciplinary Order or any portion thereof void or unenforceable.

In consideration of the foregoing, the parties consent to the entry of record and approval of this Joint Motion for Consent Order, Joint Stipulation of Facts, Waiver of Hearing Before the Missouri Board of Pharmacy and Joint Disciplinary Order with Joint Stipulated Findings of Fact and Conclusions of Law and to the termination of any further

proceedings before the Missouri Board of Pharmacy based upon the Complaint filed by the Petitioner in the above-styled action.

RESPONDENT

MED-E-QUIP LOCATORS, INC.

By:

Robert A. Caples
Robert A. Caples
Manager in Charge

Date:

9-4-09

PETITIONER

MISSOURI BOARD OF
PHARMACY

By:

Kimberly Grinston
Kimberly Grinston
Executive Director

Date:

9-11-09

GREENSFELDER, HEMKER
& GALE, P.C.

By:

Mary L. Reitz
Mary L. Reitz #37372
10 South Broadway Suite 2000
St. Louis, MO 63102
Telephone: 314/241-9090
Fax: 314/241-1265

Attorneys for Respondent

NEWMAN, COMLEY & RUTH, P.C.

By:

Lanette R. Gooch
Lanette R. Gooch #47860
601 Monroe, Suite 301
P.O. Box 537
Jefferson City, MO 65102
Telephone: 573/634-2266

Attorneys for Petitioner